1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
AN2 Therapeutics said results from a 28-day nonhuman primate study and a Phase 1 first-in-human study of its oral drug AN2-502998 for chronic Chagas disease were positive. The company plans to start a Phase 2 proof-of-concept study late this year, with the drug not yet approved and no FDA-approved Chagas treatment for adults currently available.
NHP study: 100% of treated animals achieved parasite elimination at target exposures attainable in humans, maintained through four months after treatment ended
Phase 1 study (NCT07024589) in healthy adult volunteers: generally well tolerated with no dose-limiting toxicities
Company plans to initiate a Phase 2 proof-of-concept study late this year, in collaboration with DNDi
AN2-502998 would be eligible for an FDA Tropical Disease Priority Review Voucher if approved
Samsara reported first-quarter fiscal 2027 revenue of $478.8 million, up 31% from $366.9 million a year earlier, and GAAP net income of $44.5 million, or $0.08 per share, compared with a loss of $0.04 per share a year earlier. The result includes a $30.3 million arbitration gain from its Motive matter, and the company expects revenue of $482 million to $484 million in the second quarter and $2.005 billion to $2.013 billion for fiscal 2027.
Total revenue of $478.8 million, up 31% year over year; ending ARR of $1.991 billion, up 30%.
GAAP operating income of $7.2 million, compared with a loss of $33.3 million a year earlier.
GAAP net income of $44.5 million ($0.08 per share) includes a $30.3 million arbitration award gain from the Motive matter.
Outlook: Q2 revenue of $482 million to $484 million; fiscal 2027 revenue of $2.005 billion to $2.013 billion, with GAAP profitability expected.
Argan, Inc. reported results for the three months ended April 30, 2026, with revenue up 50.2% year over year to $291.0 million and net income of $46.1 million, or $3.24 per diluted share, versus $1.60 a year earlier. Gross margin rose to 21.0% and the company held $973.6 million in cash, cash equivalents and investments with no debt, though backlog fell to $2.8 billion from $2.9 billion.
Revenue of $291.0 million, up $97.3 million or 50.2% from $193.7 million a year earlier
Net income of $46.1 million, or $3.24 per diluted share, versus $22.6 million, or $1.60, a year earlier
Project backlog of approximately $2.8 billion at April 30, 2026, down from $2.9 billion at January 31, 2026
Quarterly cash dividend of $0.500 per share versus $0.375 a year earlier
Concrete Pumping Holdings reported second-quarter fiscal 2026 results for the quarter ended April 30, 2026, with revenue up 14% to $106.8 million and income from operations up 46% to $12.1 million. Net income attributable to common shareholders was $2.1 million, or $0.04 per diluted share, compared with a loss of $0.4 million a year earlier. The company raised its fiscal 2026 outlook for revenue, Adjusted EBITDA and free cash flow.
Revenue was $106.8 million versus $94.0 million; Adjusted EBITDA rose 17.4% to $26.4 million.
Fiscal 2026 revenue outlook is now $410.0 million to $425.0 million, up from $390.0 million to $410.0 million.
Fiscal 2026 Adjusted EBITDA outlook is now $98.0 million to $105.0 million, up from $90.0 million to $100.0 million.
Debt outstanding was $425.6 million and total available liquidity was $346.3 million, compared with $352.5 million a year earlier.
Rubrik reported results for the fiscal first quarter ended April 30, 2026, with total revenue of $387.1 million, up 39% from a year earlier, and a GAAP net loss of $41.9 million, narrower than the $102.1 million loss a year earlier. The company said it is raising all of its guided metrics for fiscal 2027, now expecting revenue of $1,638 million to $1,648 million for the full year.
Total revenue was $387.1 million, up 39% from $278.5 million; subscription ARR reached $1.57 billion, up 32%.
GAAP net loss per share was $(0.21), compared with $(0.53) a year earlier; non-GAAP diluted net income per share was $0.16.
Free cash flow was $73.6 million, compared with $33.3 million, and cash and short-term investments totaled $1.75 billion as of April 30, 2026.
Fiscal 2027 outlook: revenue of $1,638 million to $1,648 million and free cash flow of $293 million to $303 million; the filing does not state the prior ranges.
Docusign reported fiscal first-quarter 2027 results for the three months ended April 30, 2026, with revenue of $830.2 million, up 9% year over year, and GAAP diluted earnings of $0.40 per share versus $0.34 a year earlier. The company also gave guidance for the quarter ending July 31, 2026, with revenue of $865 million to $869 million, and for the fiscal year ending January 31, 2027, with revenue of $3,490 million to $3,502 million, and repurchased $317.5 million of its stock during the quarter.
Revenue was $830.2 million, up 9% year over year, including an approximately 1.6% positive impact from foreign exchange rates.
GAAP net income per diluted share was $0.40 versus $0.34; non-GAAP net income per diluted share was $1.09 versus $0.90.
Free cash flow was $289.4 million versus $227.8 million, and share repurchases were $317.5 million versus $183.4 million.
Guidance calls for fiscal 2027 revenue of $3,490 million to $3,502 million, a 9% increase, and a quarter ending July 31, 2026 revenue range of $865 million to $869 million.
ServiceTitan reported fiscal first-quarter 2027 results for the period ended April 30, 2026, with total revenue up 25% to $268.8 million and a GAAP net loss of $22.8 million, down from $46.4 million a year earlier. The company also issued fiscal second-quarter revenue guidance of $284 million to $286 million and full fiscal 2027 revenue guidance of $1.13 billion to $1.14 billion, which shareholders can compare with future results.
Total revenue was $268.8 million, up 25% from $215.7 million; gross transaction volume was $21.7 billion, up 23%.
GAAP net loss was $22.8 million, or $0.24 per share, compared with a net loss of $46.4 million, or $0.51 per share, a year earlier.
Non-GAAP income from operations was $40.8 million, a 15.2% margin, versus $16.2 million (7.5%) in the prior-year quarter.
Guidance: fiscal Q2 2027 revenue of $284 million to $286 million and full fiscal 2027 revenue of $1.13 billion to $1.14 billion; the filing does not state prior guidance.
Caleres reported first quarter 2026 net sales of $666.6 million, up 8.5%, and GAAP earnings of $0.42 per diluted share, up from $0.21 a year earlier. The company raised the low end of its full-year 2026 adjusted EPS guidance to $1.40 to $1.65 from $1.35 to $1.65, which shareholders may view as a sign of improving earnings expectations.
Q1 net sales $666.6 million, up 8.5%; Brand Portfolio up 20.6%, while Famous Footwear fell 2.5%
Q1 GAAP EPS $0.42 and adjusted EPS $0.38, versus $0.21 and $0.22 a year earlier
Full-year 2026 adjusted EPS guidance $1.40 to $1.65, versus prior $1.35 to $1.65; GAAP EPS guidance $1.44 to $1.69
Q2 2026 GAAP EPS guidance of $0.32 to $0.38 with net sales expected to rise mid-to-high-single digits
Toro reported fiscal second-quarter 2026 results, with net sales up 8.1% to $1.42 billion and diluted EPS up 9.5% to $1.50 (adjusted EPS up 12.7% to $1.60). The company raised its full-year adjusted EPS guidance to $4.50 to $4.62 from $4.40 to $4.60, and raised its net sales growth range to 4.0% to 6.5% from 3.0% to 6.5%.
Q2 net sales rose 8.1% year over year to $1.42 billion; Professional segment sales rose 9.1% to $1.11 billion.
Diluted EPS was $1.50, up from $1.37; adjusted diluted EPS was $1.60, up from $1.42.
Full-year fiscal 2026 adjusted EPS guidance was raised to $4.50 to $4.62, from $4.40 to $4.60.
Company returned $228 million to shareholders through dividends and share repurchases in the quarter, and reported free cash flow of $265.5 million for the first six months.
Ciena reported fiscal second quarter 2026 revenue of $1.57 billion, up 39.5% from a year earlier, and adjusted diluted EPS of $1.64 versus $0.42. The company raised its fiscal 2026 revenue guidance to $6.3 billion plus or minus $100 million and forecast fiscal third quarter revenue of $1.625 billion plus or minus $50 million, so the results and outlook both point higher for shareholders.
Q2 fiscal 2026 revenue was $1.57 billion, compared with $1.13 billion in Q2 fiscal 2025.
GAAP diluted EPS was $1.49 versus $0.06 a year earlier; adjusted diluted EPS was $1.64 versus $0.42.
Fiscal 2026 revenue guidance raised to $6.3 billion plus or minus $100 million; fiscal Q3 revenue guidance is $1.625 billion plus or minus $50 million.
Ciena repurchased about 0.2 million shares for $83.1 million under its $1 billion repurchase program during the quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.